Is Dyne Therapeutics Inc (NASDAQ: DYN) A Stock A New Investor Should Consider Now?

Dyne Therapeutics Inc (NASDAQ:DYN) shares, rose in value on Thursday, April 04, with the stock price down by -3.34% to the previous day’s close as strong demand from buyers drove the stock to $27.80.

Actively observing the price movement in the recent trading, the stock is buoying the session at $28.76. The value of beta (5-year monthly) is 0.95. Referring to stock’s 52-week performance, its high was $30.27, and the low was $6.40. On the whole, DYN has fluctuated by 7.46% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


With the market capitalization of Dyne Therapeutics Inc currently standing at about $2.25 billion, investors are eagerly awaiting this quarter’s results, scheduled for May 09, 2024 – May 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.8, which is expected to increase to -$0.7 for fiscal year -$3.27 and then to about -$3.17 by fiscal year 2025. Data indicates that the EPS growth is expected to be 17.20% in 2025, while the next year’s EPS growth is forecast to be 3.10%.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that DYN’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of DYN currently trading nearly 1.66% and 12.98% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 54.59, while the 7-day volatility ratio is showing 6.99% which for the 30-day chart, stands at 7.38%. Furthermore, Dyne Therapeutics Inc (DYN)’s beta value is 0.95, and its average true range (ATR) is 1.89.

A comparison of Dyne Therapeutics Inc (DYN) with its peers suggests the former has fared considerably weaker in the market. DYN showed an intraday change of -3.34% in today’s session so far, and over the past year, it grew by 151.58%%.

Data on historical trading for Dyne Therapeutics Inc (NASDAQ:DYN) indicates that the trading volumes over the past 10 days have averaged 1.37 million and over the past 3 months, they’ve averaged 1.95 million. According to company’s latest data on outstanding shares, there are 61.47 million shares outstanding.

Nearly 38.45% of Dyne Therapeutics Inc’s shares belong to company insiders and institutional investors own 52.82% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 6.82 million shares as on Mar 15, 2024, resulting in a short ratio of 3.94. According to the data, the short interest in Dyne Therapeutics Inc (DYN) stood at 8.32% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 7.25 million. The stock has risen by 109.02% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the DYN stock heading into the next quarter.